1
Participants
Start Date
August 6, 2019
Primary Completion Date
January 21, 2021
Study Completion Date
January 21, 2021
TQB2450
TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
Peking University First Hospital, Beijing
Fifth Medical Center of the Chinese People's Liberation Army General Hospital, Beijing
Peking Union Medical College Hospital, Beijing
Peking University Third Hospital, Beijin
Peking Hospital, Beijin
First Affiliated Hospital of China Medical University, Shenyang
First Hospital of Jilin University, Changchun
Cancer Hospital Affiliated to Harbin Medical University, Harbin
Shanghai Tongji Hospital, Shanghai
Shanghai Tumor Hospital, Shanghai
Qilu Hospital of Shandong University, Jinan
Affiliated Hospital of Qingdao University, Qingdao
Zhejiang Tumor Hospital, Hangzhou
Union Medical College Hospital Affiliated to Fujian Medical University, Fuzhou
Hunan Canser Hospital, Changsha
Henan Cancer Hospital, Zhengzhou
Henan People's Hospital, Zhengzhou
Sun Yat-sen University Cancer Center, Guangzhou
Lead Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
INDUSTRY